15:02:27 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-13 Kvartalsrapport 2024-Q3
2024-08-21 Kvartalsrapport 2024-Q2
2024-05-15 Kvartalsrapport 2024-Q1
2024-03-21 X-dag ordinarie utdelning HLUN A 0.70 DKK
2024-03-21 X-dag ordinarie utdelning HLUN B 0.70 DKK
2024-03-20 Årsstämma 2024
2024-02-07 Bokslutskommuniké 2023
2023-11-08 Kvartalsrapport 2023-Q3
2023-08-16 Kvartalsrapport 2023-Q2
2023-05-10 Kvartalsrapport 2023-Q1
2023-03-22 X-dag ordinarie utdelning HLUN A 0.58 DKK
2023-03-22 X-dag ordinarie utdelning HLUN B 0.58 DKK
2023-03-21 Årsstämma 2023
2023-02-08 Bokslutskommuniké 2022
2022-11-09 Kvartalsrapport 2022-Q3
2022-08-17 Kvartalsrapport 2022-Q2
2022-06-10 Split HLUN B 1:5
2022-06-08 Extra Bolagsstämma 2022
2022-05-11 Kvartalsrapport 2022-Q1
2022-03-24 X-dag ordinarie utdelning HLUN B 2.00 DKK
2022-03-23 Årsstämma 2022
2022-02-09 Bokslutskommuniké 2021
2021-11-10 Kvartalsrapport 2021-Q3
2021-08-18 Kvartalsrapport 2021-Q2
2021-05-11 Kvartalsrapport 2021-Q1
2021-03-24 X-dag ordinarie utdelning HLUN B 2.50 DKK
2021-03-23 Årsstämma 2021
2021-02-04 Bokslutskommuniké 2020
2020-11-03 Kvartalsrapport 2020-Q3
2020-08-13 Kvartalsrapport 2020-Q2
2020-05-12 Kvartalsrapport 2020-Q1
2020-03-25 X-dag ordinarie utdelning HLUN B 4.10 DKK
2020-03-24 Årsstämma 2020
2020-02-06 Bokslutskommuniké 2019
2019-11-05 Kvartalsrapport 2019-Q3
2019-08-14 Kvartalsrapport 2019-Q2
2019-05-08 Kvartalsrapport 2019-Q1
2019-03-27 X-dag ordinarie utdelning HLUN B 12.00 DKK
2019-03-26 Årsstämma 2019
2019-02-05 Bokslutskommuniké 2018
2018-11-07 Kvartalsrapport 2018-Q3
2018-08-08 Kvartalsrapport 2018-Q2
2018-05-08 Kvartalsrapport 2018-Q1
2018-03-21 X-dag ordinarie utdelning HLUN B 8.00 DKK
2018-03-20 Årsstämma 2018
2018-02-07 Bokslutskommuniké 2017
2017-11-08 Kvartalsrapport 2017-Q3
2017-08-09 Kvartalsrapport 2017-Q2
2017-05-10 Kvartalsrapport 2017-Q1
2017-03-31 X-dag ordinarie utdelning HLUN B 2.45 DKK
2017-03-30 Årsstämma 2017
2017-02-08 Bokslutskommuniké 2016
2016-11-02 Kvartalsrapport 2016-Q3
2016-08-24 Kvartalsrapport 2016-Q2
2016-05-11 Kvartalsrapport 2016-Q1
2016-04-01 X-dag ordinarie utdelning HLUN B 0.00 DKK
2016-03-31 Årsstämma 2016
2016-02-10 Bokslutskommuniké 2015
2015-11-04 Kvartalsrapport 2015-Q3
2015-08-19 Kvartalsrapport 2015-Q2
2015-05-06 Kvartalsrapport 2015-Q1
2015-03-26 X-dag ordinarie utdelning HLUN B 0.00 DKK
2015-03-25 Årsstämma 2015
2015-02-05 Bokslutskommuniké 2014
2014-11-05 Kvartalsrapport 2014-Q3
2014-08-07 Kvartalsrapport 2014-Q2
2014-05-07 Kvartalsrapport 2014-Q1
2014-03-27 X-dag ordinarie utdelning HLUN B 2.77 DKK
2014-03-26 Årsstämma 2014
2014-02-06 Bokslutskommuniké 2013
2013-11-06 Kvartalsrapport 2013-Q3
2013-08-07 Kvartalsrapport 2013-Q2
2013-05-01 Kvartalsrapport 2013-Q1
2013-03-22 X-dag ordinarie utdelning HLUN B 2.00 DKK
2013-03-21 Årsstämma 2013
2013-02-06 Bokslutskommuniké 2012
2012-11-07 Kvartalsrapport 2012-Q3
2012-08-08 Kvartalsrapport 2012-Q2
2012-05-02 Kvartalsrapport 2012-Q1
2012-03-30 X-dag ordinarie utdelning HLUN B 3.49 DKK
2012-03-29 Årsstämma 2012
2012-02-08 Bokslutskommuniké 2011
2011-11-09 Kvartalsrapport 2011-Q3
2011-08-10 Kvartalsrapport 2011-Q2
2011-05-04 Kvartalsrapport 2011-Q1
2011-03-31 X-dag ordinarie utdelning HLUN B 3.77 DKK
2011-03-30 Årsstämma 2011
2010-04-21 X-dag ordinarie utdelning HLUN B 3.07 DKK
2009-04-22 X-dag ordinarie utdelning HLUN B 2.30 DKK

Beskrivning

LandDanmark
ListaLarge Cap Copenhagen
SektorHälsovård
IndustriLäkemedel & Handel
Lundbeck är ett läkemedelsbolag. Störst fokus återfinns inom forskning om psykiatriska och neurotiska störningar, vilket innefattar behandling av depression, schizofreni, Alzheimers och Parkinsons syndrom. Bolaget bedriver forskning, utveckling och distribution av läkemedel där kundbasen återfinns på global nivå. Bolaget grundades ursprungligen under 1915 och har sitt huvudkontor i Valby.
2023-11-08 07:30:20

Key highlights

Lundbeck's revenue increased by 10% (+9% CER[1]) to DKK 14,934 million in the first nine months of 2023, driven mainly by growth in the U.S. and Europe
  • United States: DKK 7,317 million (+11%; +13% CER)
  • Europe: DKK 3,454 million (+10%; +11% CER)
  • International Markets: DKK 3,926 million (-2%; +3% CER)
The revenue of Lundbeck's strategic brands increased by 14% (+16% CER), reaching DKK 10,091 million, representing 68% of total revenue
  • Rexulti[®]/Rxulti[®]: DKK 3,309 million (+17%; +19% CER)
  • Brintellix[®]/Trintellix[®]: DKK 3,207 million (+1%; +4% CER)
  • Abilify Maintena[®]/Asimtufii: DKK 2,374 million (+10%; +11% CER)
  • Vyepti[®]: DKK 1,201 million (+79%; +81% CER)

Adjusted EBITDA[2] increased to DKK 4,859 million (+31%; +20% CER) and adjusted EBITDA margin reached 32.5% equivalent to an increase of 5.2 percentage points. Adjusted earnings per share (EPS) reached DKK 3.65 equivalent to an increase of 27%.
 

In connection with the corporate release, Lundbeck's President and CEO, Charl van Zyl said:

"In my first two months at Lundbeck, I have witnessed a highly skilled team and a solid foundation for advancing the company's objectives of long-term growth. Lundbeck has strong momentum and is delivering a robust performance, achieving a revenue of DKK 15 billion in the first nine months, and allowing for a slight guidance upgrade. We are committed to investing in our pipeline, building upon a successful R&D transformation for the company's future progress."

Key figures

[][]
DKK 9M 9M Change Change Q3 Q3 2022 Change Change
million 2023 2022 (CER)[1] 2023 (CER)[1]
Revenue 14,934 13,566 10% 9% 4,952 4,719 5% 7%
EBITDA 4,463 3,753 19% 9% 1,385 1,414 (2%) (7%)
Adjusted 4,859 3,705 31% 20% 1,521 1,414 8% 1%
EBITDA
EPS (DKK) 2.17 1.62 34% 0.68 0.69 (1%)
Adjusted 3.65 2.87 27% 1.17 1.05 11%
EPS (DKK)

Recent events

On September 1, 2023, Charl van Zyl joined as new President and CEO of Lundbeck as announced on June 26, 2023.

On September 7, 2023, Lundbeck and Otsuka Pharmaceutical, Co., Ltd. announced topline results from two phase III trials of brexpiprazole as combination therapy with sertraline for the treatment of Post-Traumatic Stress Disorder in adults. Overall, the safety and tolerability results were consistent with the profile of brexpiprazole as observed in the clinical trials for schizophrenia, agitation associated with dementia due to Alzheimer's disease (AADAD), and adjunctive treatment of major depressive disorder (MDD).

On September 14, 2023, Lundbeck presented clinical data from a phase IIa Proof of Concept trial on Lu AG09222 in migraine prevention at the International Headache Congress in Seoul, Korea. The data supports Lu AG09222 as a potential preventive treatment of migraine and based on this positive outcome. Lu AG09222 is progressing into further trials to expand its route of administration opportunities and dose-response relationship.

2023 Guidance

Lundbeck has narrowed its full-year guidance for revenue and now expects revenue to reach DKK 19.8 to 20.1 billion compared to previously DKK 19.5 to 20.1 billion. The financial guidance for Adjusted EBITDA has been narrowed and raised due to lower than expected R&D costs. Adjusted EBITDA is now expected to reach DKK 5.6 to 5.8 billion compared to previously DKK 5.2 to 5.6 billion. Further details are available in section 2.8 Outlook.
 

[1] Constant Exchange Rates (CER) previously denominated Local Currency (LC). Change at CER does not include effects from hedging.

[2] EBITDA refers to Earnings Before Interest, Taxes, Depreciation and Amortization. Adjusted EBITDA is defined as EBITDA adjusted by certain items, for details see section 4 Notes, note 3 Adjusted EBITDA.